In vivo gene delivery by nonviral vectors: Overcoming hurdles

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1298-1304

  Zhang, Yuan ^a   Satterlee, Andrew ^a   Huang, Leaf ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DIOLEOYLPHOSPHATIDIC ACID; GOLD NANOPARTICLE; LIPOPLEX; LIPOPOLYPLEX; LIPOSOME; MACROGOL; PLASMID DNA; POLYGLACTIN; POLYPLEX; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ABLATION THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CONFERENCE PAPER; DRUG SPECIFICITY; DRUG TARGETING; ENDOSOME; ENZYME DEGRADATION; ENZYME INACTIVATION; GENE VECTOR; GLIOMA; HUMAN; IN VIVO GENE TRANSFER; INNATE IMMUNITY; INTRACELLULAR TRANSPORT; LIPOSOMAL GENE DELIVERY SYSTEM; LOCAL GENE DELIVERY; MAGNETOFECTION; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR LOCALIZATION SIGNAL; PHOTOTHERAPY; PROSTATE CANCER; RETICULOENDOTHELIAL SYSTEM; SOLID TUMOR; ULTRASOUND;

EID: 84863485635     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.79     Document Type: Review

References (71)

1. Elsabahy, M, Nazarali, A and Foldvari, M (2011). Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv 8: 235-244.
2. Monaghan, M and Pandit, A (2011). RNA interference therapy via functionalized scaffolds. Adv Drug Deliv Rev 63: 197-208.
3. Vickers, TA, Lima, WF, Wu, H, Nichols, JG, Linsley, PS and Crooke, ST (2009). Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1. Nucleic Acids Res 37: 6927-6941.
4. Jackson, AL, Bartz, SR, Schelter, J, Kobayashi, SV, Burchard, J, Mao, M et al. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637. (Pubitemid 36638089)
5. Fedorov, Y, King, A, Anderson, E, Karpilow, J, Ilsley, D, Marshall, W et al. (2005). Different delivery methods-different expression profiles. Nat Methods 2: 241. (Pubitemid 41130991)
6. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. Oligonucleotides 19: 89-102.
7. Czech, MP, Aouadi, M and Tesz, GJ (2011). RNAi-based therapeutic strategies for metabolic disease. Nat Rev Endocrinol 7: 473-484.
8. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505. (Pubitemid 43257617)
9. Gao, Y, Liu, XL and Li, XR (2011). Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine 6: 1017-1025.
10. Pan, X, Thompson, R, Meng, X, Wu, D and Xu, L (2011). Tumor-targeted RNAinterference: functional non-viral nanovectors. Am J Cancer Res 1: 25-42.
11. Wolff, JA and Rozema, DB (2008). Breaking the bonds: non-viral vectors become chemically dynamic. Mol Ther 16: 8-15.
12. Li, SD and Huang, L (2010). Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 145: 178-181.
13. Tseng, YC, Mozumdar, S and Huang, L (2009). Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 61: 721-731.
14. Schipper, ML, Iyer, G, Koh, AL, Cheng, Z, Ebenstein, Y, Aharoni, A et al. (2009). Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 5: 126-134.
15. Seymour, LW (1992). Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135-187.
16. Drummond, DC, Zignani, M and Leroux, J (2000). Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39: 409-460.
17. Guo, X and Szoka, FC Jr (2001). Steric stabilization of fusogenic liposomes by a lowpH sensitive PEG-diortho ester-lipid conjugate. Bioconjug Chem 12: 291-300. (Pubitemid 32235482)
18. Walker, GF, Fella, C, Pelisek, J, Fahrmeir, J, Boeckle, S, Ogris, M et al. (2005). Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther 11: 418-425. (Pubitemid 40277318)
19. Hatakeyama, H, Akita, H, Ito, E, Hayashi, Y, Oishi, M, Nagasaki, Y et al. (2011). Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumorspecific cleavable PEG-lipid. Biomaterials 32: 4306-4316.
20. Hatakeyama, H, Akita, H and Harashima, H (2011). A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63: 152-160.
21. Hatakeyama, H, Akita, H, Kogure, K, Oishi, M, Nagasaki, Y, Kihira, Y et al. (2007). Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 14: 68-77. (Pubitemid 44942867)
22. Romberg, B, Hennink, WE and Storm, G (2008). Sheddable coatings for longcirculating nanoparticles. Pharm Res 25: 55-71.
23. Huang, L and Liu, Y (2011). In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 13: 507-530.
24. Sun, W, Du, L and Li, M (2011). Advances and perspectives in cell-specific aptamers. Curr Pharm Des 17: 80-91.
25. Sawant, R and Torchilin, V (2010). Intracellular transduction using cell-penetrating peptides. Mol Biosyst 6: 628-640.
26. Manjappa, AS, Chaudhari, KR, Venkataraju, MP, Dantuluri, P, Nanda, B, Sidda, C et al. (2011). Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 150: 2-22.
27. Chen, Y, Wu, JJ and Huang, L (2010). Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 18: 828-834.
28. Chen, Y, Bathula, SR, Yang, Q and Huang, L (2010). Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol 130: 2790-2798.
29. Huang, S, Li, J, Han, L, Liu, S, Ma, H, Huang, R et al. (2011). Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 32: 6832-6838.
30. Díez, S, Navarro, G and de ILarduya, CT (2009). In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med 11: 38-45.
31. Hafez, IM, Maurer, N and Cullis, PR (2001). On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8: 1188-1196. (Pubitemid 32776393)
32. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
33. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364.
34. Fella, C, Walker, GF, Ogris, M and Wagner, E (2008). Amine-reactive pyridylhydrazonebased PEG reagents for pH-reversible PEI polyplex shielding. Eur J Pharm Sci 34: 309-320.
35. Asayama, S, Sudo, M, Nagaoka, S and Kawakami, H (2008). Carboxymethyl poly(Lhistidine) as a new pH-sensitive polypeptide to enhance polyplex gene delivery. Mol Pharm 5: 898-901.
36. West, KR and Otto, S (2005). Reversible covalent chemistry in drug delivery. Curr Drug Discov Technol 2: 123-160. (Pubitemid 41242960)
37. Zalipsky, S, Qazen, M, Walker, JA 2nd, Mullah, N, Quinn, YP and Huang, SK (1999). New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 10: 703-707. (Pubitemid 29456355)
38. Mok, H, Veiseh, O, Fang, C, Kievit, FM, Wang, FY, Park, JO et al. (2010). pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm 7: 1930-1939.
39. Pak, CC, Erukulla, RK, Ahl, PL, Janoff, AS and Meers, P (1999). Elastase activated liposomal delivery to nucleated cells. Biochim Biophys Acta 1419: 111-126. (Pubitemid 29322703)
40. Hatakeyama, H, Ito, E, Akita, H, Oishi, M, Nagasaki, Y, Futaki, S et al. (2009). A pHsensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Release 139: 127-132.
41. Sakurai, Y, Hatakeyama, H, Sato, Y, Akita, H, Takayama, K, Kobayashi, S et al. (2011). Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 32: 5733-5742.
42. Li, J, Chen, YC, Tseng, YC, Mozumdar, S and Huang, L (2010). Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 142: 416-421.
43. Bolhassani, A (2011). Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 1816: 232-246.
44. Collas, P and Aleström, P (1996). Nuclear localization signal of SV40 T antigen directs import of plasmid DNA into sea urchin male pronuclei in vitro. Mol Reprod Dev 45: 431-438. (Pubitemid 26408782)
45. Vacik, J, Dean, BS, Zimmer, WE and Dean, DA (1999). Cell-specific nuclear import of plasmid DNA. Gene Ther 6: 1006-1014. (Pubitemid 29295205)
46. Grandinetti, G, Smith, AE and Reineke, TM (2012). Membrane and nuclear permeabilization by polymeric pDNA vehicles: efficient method for gene delivery or mechanism of cytotoxicity? Mol Pharm 9: 523-538.
47. Grandinetti, G, Ingle, NP and Reineke, TM (2011). Interaction of poly(ethylenimine)-DNA polyplexes with mitochondria: implications for a mechanism of cytotoxicity. Mol Pharm 8: 1709-1719.
48. Shim, MS and Kwon, YJ (2010). Efficient and targeted delivery of siRNA in vivo. FEBS J 277: 4814-4827.
49. Tsai, LR, Chen, MH, Chien, CT, Chen, MK, Lin, FS, Lin, KM et al. (2011). A singlemonomer derived linear-like PEI-co-PEG for siRNA delivery and silencing. Biomaterials 32: 3647-3653.
50. Yin, Q, Gao, Y, Zhang, Z, Zhang, P and Li, Y (2011). Bioreducible poly (ß-amino esters)/shRNA complex nanoparticles for efficient RNA delivery. J Control Release 151: 35-44.
51. Wagner, E (2011). Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise. Acc Chem Res (epub ahead of print).
52. Schaffert, D, Troiber, C, Salcher, EE, Fröhlich, T, Martin, I, Badgujar, N et al. (2011). Solid-phase synthesis of sequence-defined T-, i-, and U-shape polymers for pDNA and siRNA delivery. Angew Chem Int Ed Engl 50: 8986-8989.
53. Li, SD and Huang, L (2006). Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 3: 579-588. (Pubitemid 44639135)
54. Li, SD, Chen, YC, Hackett, MJ and Huang, L (2008). Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16: 163-169.
55. Li, SD, Chono, S and Huang, L (2008). Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 16: 942-946. (Pubitemid 351587105)
56. Lee, RJ and Huang, L (1996). Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem 271: 8481-8487. (Pubitemid 26108687)
57. Chono, S, Li, SD, Conwell, CC and Huang, L (2008). An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 131: 64-69.
58. Chen, Y, Zhu, X, Zhang, X, Liu, B and Huang, L (2010). Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18: 1650-1656.
59. Perche, F, Benvegnu, T, Berchel, M, Lebegue, L, Pichon, C, Jaffrès, PA et al. (2011). Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7: 445-453.
60. Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154-157.
61. Kogure, K, Akita, H, Yamada, Y and Harashima, H (2008). Multifunctional envelopetype nano device (MEND) as a non-viral gene delivery system. Adv Drug Deliv Rev 60: 559-571. (Pubitemid 351215573)
62. Wang, KY, McCurdy, S, Shea, RG, Swaminathan, S and Bolton, PH (1993). A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry 32: 1899-1904. (Pubitemid 23086037)
63. Esposito, CL, Catuogno, S, de Franciscis, V and Cerchia, L (2011). New insight into clinical development of nucleic acid aptamers. Discov Med 11: 487-496.
64. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015. (Pubitemid 44215395)
65. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
66. Suzuki, R, Takizawa, T, Negishi, Y, Utoguchi, N, Sawamura, K, Tanaka, K et al. (2008). Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles. J Control Release 125: 137-144. (Pubitemid 350299602)
67. Negishi, Y, Omata, D, Iijima, H, Takabayashi, Y, Suzuki, K, Endo, Y et al. (2010). Enhanced laminin-derived peptide AG73-mediated liposomal gene transfer by bubble liposomes and ultrasound. Mol Pharm 7: 217-226.
68. Chumakova, OV, Liopo, AV, Andreev, VG, Cicenaite, I, Evers, BM, Chakrabarty, S et al. (2008). Composition of PLGA and PEI/DNA nanoparticles improves ultrasoundmediated gene delivery in solid tumors in vivo. Cancer Lett 261: 215-225.
69. Bardhan, R, Lal, S, Joshi, A and Halas, NJ (2011). Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res 44: 936-946.
70. Ni, X, Zhang, Y, Ribas, J, Chowdhury, WH, Castanares, M, Zhang, Z et al. (2011). Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121: 2383-2390.
71. Wang, C, Ding, C, Kong, M, Dong, A, Qian, J, Jiang, D et al. (2011). Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem Biophys Res Commun 410: 537-542.